Table 4 Overall survival – multivariable Cox models of breast cancer subgroups.
Subset | IGHM HR | IGHM p value | IGHA2 HR | IGHA2 p value | IGJ HR | IGJ p value | IGHG1 HR | IGHG1 p value |
|---|---|---|---|---|---|---|---|---|
ER/HER2 subgroups, models adjusted for grade, size, node status, age, chemotherapy | ||||||||
ER− PR− HER2−, n = 133, events = 24 | 0.74 0.50–1.10 | 0.141 | 0.47 0.29–0.77 | 0.002 | 0.58 0.36–0.93 | 0.025 | 0.68 0.44–1.05 | 0.081 |
ER+ HER2−, n = 2324, events = 202 | 0.88 0.76–1.02 | 0.089 | 0.91 0.79–1.05 | 0.189 | 0.92 0.79–1.06 | 0.241 | 0.89 0.77–1.03 | 0.120 |
ER+ HER2−, age < 66, n = 1213, events = 53 | 0.72 0.53–0.96 | 0.026 | 0.72 0.55–0.95 | 0.018 | 0.70 0.53–0.93 | 0.015 | 0.71 0.52–0.96 | 0.026 |
HER2+, n = 382, events = 46 | 0.83 0.60–1.15 | 0.261 | 0.79 0.55–1.14 | 0.205 | 0.85 0.59–1.23 | 0.396 | 0.81 0.60–1.11 | 0.189 |
PAM50 subgroups, models adjusted for size, node status, age, chemotherapy | ||||||||
Basal, n = 314, events = 62 | 0.79 0.61–1.02 | 0.066 | 0.68 0.52–0.88 | 0.003 | 0.69 0.51–0.94 | 0.019 | 0.78 0.60–1.02 | 0.074 |
HER2 enriched, n = 298, events = 48 | 0.80 0.60–1.06 | 0.116 | 0.72 0.53–0.98 | 0.036 | 0.76 0.55–1.05 | 0.097 | 0.76 0.57–1.00 | 0.049 |
Luminal A, n = 1597, events = 110 | 0.83 0.66–1.04 | 0.112 | 0.95 0.77–1.17 | 0.620 | 0.92 0.75–1.13 | 0.416 | 0.83 0.65–1.05 | 0.119 |
Luminal A, age<65, n = 798, events = 19 | 0.58 0.31–1.08 | 0.086 | 0.62 0.36–1.08 | 0.090 | 0.61 0.36–1.04 | 0.070 | 0.50 0.26–0.96 | 0.037 |
Luminal B, n = 706, events = 76 | 0.93 0.76–1.13 | 0.459 | 0.91 0.71–1.15 | 0.424 | 0.87 0.67–1.14 | 0.316 | 0.89 0.72–1.10 | 0.293 |
Luminal B, age < 66, n = 373, events = 21 | 0.77 0.51–1.16 | 0.210 | 0.74 0.46–1.17 | 0.195 | 0.70 0.42–1.17 | 0.175 | 0.91 0.60–1.36 | 0.636 |
